Letter to the Editor
Call for Participants: Synovial Cell Sarcoma
An ESUN Feature
The Surgery Branch of the National Cancer Institute has developed a new treatment for patients with Synovial Cell Sarcoma. This treatment involves a new approach to immunotherapy which takes advantage of the patient’s own immune system to treat the disease. In this treatment, normal lymphocytes (circulating blood cells) are removed from the patient, genetically modified to enable them to attack the cancer, and then large numbers of these cells are returned to the patient. We have recently begun this trial and have already seen promising results.
Eligibility for this trial includes only patients who express the tissue typing molecule, HLA-A*0201 (present in approximately 50% of individuals), and whose tumor expresses the NY-ESO-1 tumor antigen (about 80% of patients with synovial cell sarcoma). Some patients with sarcomas other than synovial cell sarcoma may also be eligible
We are now actively seeking patients for this clinical trial. We will perform the tests for eligibility at our expense. There is no charge for treatment at the National Cancer Institute.
To refer a patient please contact:
June Kryk or Linda Williams
Immunotherapy Referral Office
CRC,Room 2-1730
10 Center Drive
Bethesda, MD 20892
Telephone: (301) 451-1929
Fax: (301) 451-1927
E-mail: Jkryk@cc.nih.gov or Lwilliams@cc.nih.gov
Thank you in advance for your help in attempting to find new treatments for patients with this difficult disease.
Sincerely,
Steven A. Rosenberg, M.D., Ph.D
Chief of Surgery
National Cancer Institute
CRC, Room 3-3940
10 Center Drive
Bethesda, MD 20892
(301) 496-4164
V5N6 ESUN Copyright © 2008 Liddy Shriver Sarcoma Initiative.